Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
282.55
-3.20 (-1.12%)
At close: Nov 16, 2026, 4:00 PM EST
279.00
-3.55 (-1.26%)
Pre-market: Nov 17, 2026, 9:23 AM EST
Johnson & Johnson Revenue
Johnson & Johnson had revenue of $25.40B in the quarter ending September 27, 2026, with 5.86% growth. This brings the company's total for the last twelve months to $99.34B, up 7.80% year-over-year. In the year 2025, Johnson & Johnson had annual revenue of $94.19B with 6.05% growth. That makes Johnson & Johnson the 87th largest company in the world by revenue and 38th in the United States.
Revenue (ttm)
$99.34B
Revenue Growth
+7.80%
P/S Ratio
6.85
Revenue / Employee
$718,777
Employees
138,200
Market Cap
680.19B
Revenue by Segment
Fiscal year ended Dec 28, 2025 See the full Johnson & Johnson breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 28, 2025 | 94.19B | 5.37B | 6.05% |
| Dec 29, 2024 | 88.82B | 3.66B | 4.30% |
| Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
| Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
| Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
| Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
| Dec 29, 2019 | 82.06B | 478.00M | 0.59% |
| Dec 30, 2018 | 81.58B | 5.13B | 6.71% |
| Dec 31, 2017 | 76.45B | 4.56B | 6.34% |
| Jan 1, 2017 | 71.89B | 1.82B | 2.59% |
| Jan 3, 2016 | 70.07B | -4.26B | -5.73% |
| Dec 28, 2014 | 74.33B | 3.02B | 4.23% |
| Dec 29, 2013 | 71.31B | 4.09B | 6.08% |
| Dec 30, 2012 | 67.22B | 2.19B | 3.37% |
| Jan 1, 2012 | 65.03B | 3.44B | 5.59% |
| Jan 2, 2011 | 61.59B | -310.00M | -0.50% |
| Jan 3, 2010 | 61.90B | -1.85B | -2.90% |
| Dec 28, 2008 | 63.75B | 2.65B | 4.34% |
| Dec 30, 2007 | 61.10B | 7.77B | 14.57% |
| Dec 31, 2006 | 53.32B | 2.81B | 5.56% |
| Jan 1, 2006 | 50.51B | 3.17B | 6.69% |
| Jan 2, 2005 | 47.35B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Eli Lilly and Company | 86.46B |
| Merck & Co. | 67.38B |
| AbbVie | 66.01B |
| Pfizer | 63.62B |
| AstraZeneca | 62.38B |
| Sanofi | 57.89B |
| Novartis AG | 57.36B |
| Novo Nordisk | 50.70B |
JNJ News
- 1 day ago - Blackstone Life Sciences announces $750M R&D funding agreement - TheFly
- 1 day ago - Johnson & Johnson to Buy Ollin Biosciences for $2.2 Billion - WSJ
- 1 day ago - Johnson & Johnson to acquire Ollin Biosciences for $2.2B upfront - TheFly
- 1 day ago - Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology - Business Wire
- 1 day ago - M&A News: Johnson & Johnson Has $3.4B Eye Biotech Ollin Biosciences in Its Sights - TipRanks
- 5 days ago - Massachusetts Woman's Family Awarded $3.3 Million Against Johnson & Johnson in Mesothelioma Case - Business Wire
- 6 days ago - Johnson & Johnson’s Caplyta shows improvement in Phase 2 bipolar mania study - TheFly
- 7 days ago - J&J eyes US nod for Caplyta in bipolar mania after second trial win - Reuters